

Interim Report

Quarter 3, 2026



Stable volumes, resilient profitability and strong cash flow

Quarter 3, 2026

- Net sales increased 4.1% to SEK 36,060m (34,638)
- Organic sales growth amounted to -0.3%, of which volume accounted for -0.1% and price/mix -0.2%.
- EBITA amounted to SEK 3,636m (5,152)
- EBITA excl. IAC amounted to SEK 4,725m (5,056)
- The EBITA margin excl. IAC amounted to 13.1% (14.6)
- ROCE amounted to 11.9% (17.9) and ROCE excl. IAC was 15.5% (17.6)
- Profit for the period was SEK 2,346m (3,358)
- Earnings per share was SEK 3.47 (4.86)
- Operating cash flow amounted to SEK 5,783m (5,324)
- Essity has entered into an agreement to acquire Kenvue's feminine care business in Brazil. The completion of the transaction is expected to close during the second quarter of 2027.

-0.3%

Organic sales growth

13.1%

EBITA margin excl. IAC

Financial overview

	2026:3	2025:3	%	2609	2509	%
Net sales, SEKm	36,060	34,638	4	104,298	103,799	0
Organic sales growth, %	-0.3	0.9		0.1	1.7	
Gross profit margin, %	30.0	33.5		32.0	33.2	
Gross profit margin excl. IAC, %	31.7	33.4		32.6	33.2	
EBITA, SEKm	3,636	5,152	-29	12,189	14,498	-16
EBITA margin, %	10.1	14.9		11.7	14.0	
EBITA excl. IAC, SEKm	4,725	5,056	-7	14,013	14,455	-3
EBITA margin excl. IAC, %	13.1	14.6		13.4	13.9	
Profit for the period, SEKm	2,346	3,358	-30	7,940	9,494	-16
Earnings per share, SEK	3.47	4.86	-29	11.65	13.68	-15
Earnings per share*, SEK	4.92	5.01	-2	14.44	14.37	0
ROCE, %	11.9	17.9		14.7	16.8	
ROCE excl. IAC, %	15.5	17.6		16.4	17.1	
Operating cash flow, SEKm	5,783	5,324	9	12,927	10,629	22
Net debt/EBITDA excl. IAC				0.98	1.18	

* Earnings per share excl. IAC and amortization of acquisition-related intangible assets



CEO's comments

Essity's development in the third quarter was characterized by stability and resilience in a challenging market. Profitability remained good despite intensifying cost headwinds, and cash flow was strong. Volumes were stable, and we strengthened our market positions in several strategic segments, demonstrating the competitiveness of our business. At the same time, the Group's sales development was not at the level we are aiming for, and we continue our efforts to accelerate profitable growth and offset higher costs through price increases and efficiency improvements. Cost savings were delivered according to plan, investments in marketing and customer offerings are yielding results, and sales prices were higher than in the second quarter of this year.

Demonstrated strength across several categories

Health & Medical delivered organic growth and good profitability during the quarter. Incontinence Products continued to grow, and the sales development in Medical Solutions was positive, with good growth in wound care. Sales in Personal Care also performed well, supported by continued high growth and increased market shares in Incontinence Products and Feminine Care. Consumer Tissue had lower sales due to lower volumes, primarily driven by optimization of the production footprint in Latin America, and price reductions in previous quarters. In Professional Hygiene, profitability remained solid, although volume development was not satisfactory. The decline was concentrated to the base assortment and smaller distributors which were more affected by the weaker market. However, we continued to grow in strategic products and increased sales to our larger distributors and customers.

Product launches and price increases

During the quarter, we launched new and improved products across several categories to further

strengthen our offering. For example, we expanded our range of compression garments with JOBST® Elvarex® Soft ready-to-wear, allowing us to reach patients more quickly.

We continued to actively work on price increases to offset higher costs, and all business areas reported higher sales prices compared with the second quarter.

"Our focus is on translating strong market positions into profitable growth"

Another acquisition in feminine care

During the quarter, we took another step forward in our strategy to grow in attractive, value-creating categories by entering into an agreement to acquire Kenvue's feminine care business in Brazil. The acquisition includes the market-leading brands Carefree, Sempre Livre and o.b., and strengthens Essity's position in feminine care in Latin America. Brazil represents a significant growth opportunity in hygiene and health, where we already hold a leading position in incontinence products with TENA. This acquisition follows our previous feminine care acquisition in North America and represents another concrete step in the expansion of our feminine care business, where we have a proven track record of success and see good potential for profitable growth. The transaction is subject to regulatory approval and is expected to close in the second quarter of 2027.

Strategic review of Consumer Tissue

The strategic review of Consumer Tissue is proceeding according to plan. We have assessed the conditions for a separation and are now ready to move forward with evaluating the value creation potential of the different strategic alternatives - a separation or Consumer Tissue remaining part of Essity. The ambition is to identify the

alternative that provides the best opportunity for both Consumer Tissue and Essity to reach their full potential and maximize long-term value creation.

Focus on higher growth

Our focus is on translating strong market positions into profitable growth. We continue to prioritize investments where we see the greatest opportunities to grow and create value, while improving efficiency and addressing increasing cost headwinds through pricing and cost measures. In parallel, we continue to develop our portfolio. We have clear priorities and will now ensure that our initiatives have a greater impact on the Group's growth and profitability.



Ulrika Kolsrud

President and CEO

Group

Net sales

Net sales increased 4.1% in the third quarter of 2026 compared with the corresponding period a year ago and amounted to SEK 36,060m (34,638). The acquisition in Feminine Care in North America increased the Group's consolidated net sales by 1.9%.

Organic sales decreased 0.3%, primarily as a result of price reductions in previous quarters. Sales prices were higher in the quarter compared with the second quarter across all business areas. The product mix developed positively and volumes were stable.

Growth was positive in North America, with a high growth in both Health & Medical and Personal Care. In Europe and Latin America, organic sales were slightly lower, primarily due to reduced sales in Consumer Tissue.

Change in net sales

%	2026:3 vs 2025:3
Total	4.1
Volume	-0.1
Price/Mix	-0.2
Organic growth	-0.3
Acquisitions	1.9
Divestments	0.0
Currency translation	2.5

Operating profit


The gross profit margin amounted to 30.0% (33.5). The gross profit margin excl. IAC amounted to 31.7% (33.4). Costs of goods sold were higher, mainly due to increased costs for raw materials and energy. Savings in costs of goods sold amounted to approximately SEK 180m.

EBITA amounted to SEK 3,636m (5,152) and EBITA excl. IAC amounted to SEK 4,725m (5,056). The EBITA margin excl. IAC amounted to 13.1% (14.6). Sales and administration costs amounted to 18.6% (18.8), of which marketing costs amounted to 5.2% (5.2). Cost savings in sales and administration amounted to approximately SEK 150m. IAC amounted to SEK -1,089m (96), of which approximately SEK 450m was attributable to the cost savings program and approximately SEK 500m to optimization of the production footprint in Consumer Tissue in Latin America.

Change in EBITA excl. IAC

	SEKm
EBITA excl. IAC 2025:3	5,056
Volume	80
Price/Mix	-77
Cost of goods sold	-658
Sales & Admin	148
Currency translation	163
Acquisitions & Divestments	13
EBITA excl. IAC 2026:3	4,725

Net sales 2609 by business area




Net sales 2609 by region



Net sales



EBITA excl. IAC



Financial items

Financial items decreased to SEK -275m (-369), on account of lower interest rates and lower average net debt.

Tax

The tax expense was SEK 749m (1,178), corresponding to a tax rate of 24.2% (26.0). The tax expense excl. IAC was SEK 1,044m (1,151), corresponding to a tax rate of 25.0% (25.9).

Profit for the period

Profit for the period was SEK 2,346m (3,358).


Cash flow

Operating cash flow amounted to SEK 5,783m (5,324). The increase compared with a year ago was mainly related to more favorable development in working capital, which was partly offset by higher payments for restructuring costs. Net cash flow totaled SEK 3,621m (2,933). During the quarter, Essity bought back 4,101,510 own Class B shares for a total amount of SEK 1,117m.

Operating cash flow statement

SEKm	2026:3	2025:3	2609	2509
Operating cash surplus	6,635	6,757	19,417	19,484
Change in inventories	56	-8	-673	-1,622
Change in operating receivables	464	772	-1,529	79
Change in operating liabilities	752	-364	1,813	-1,726
Investments in non-current assets, net	-1,506	-1,657	-4,244	-4,438
Restructuring costs, etc.	-513	-67	-1,423	-575
Investments in operating assets through leases	-105	-109	-434	-573
Operating cash flow	5,783	5,324	12,927	10,629
Financial items	-275	-369	-832	-1,075
Income taxes paid	-770	-873	-3,094	-3,460
Other	—	—	16	27
Cash flow from current operations	4,738	4,082	9,017	6,121
Acquisitions of Group companies and other operations	—	—	-3,087	—
Divestments of Group companies and other operations	—	5	—	5
Cash flow before transactions with shareholders	4,738	4,087	5,930	6,126
Dividend	—	—	-5,956	-5,711
Dividend to non-controlling interests	—	-7	—	-11
Repurchase of own shares	-1,117	-1,147	-2,283	-2,605
Net cash flow	3,621	2,933	-2,309	-2,201

Operating cash flow



Financial position


Net debt decreased SEK 1,591m compared with December 31, 2025 and amounted to SEK 24,952m. The decrease is mainly related to revaluation of pension assets and pension obligations. Net cash flow increased net debt by SEK 2,309m. The Group's interest-bearing gross debt amounted to SEK 35,208m (35,187) at the end of the quarter. The average maturity period was 2.6 years (3.6).

Compared with December 31, 2025, working capital increased to SEK 15,304m, mainly due to higher valuation of energy derivatives and increased trade receivables. Working capital amounted to 10.6% (9.2) of net sales.


Share buyback program

Between July 1 and September 30, 2026, Essity bought back 4,101,510 own Class B shares for a total amount of SEK 1,117m. The buybacks are part of the buyback program for SEK 3bn that Essity announced on April 22, 2026. The buyback program extends from May 12, 2026 until the 2027 Annual General Meeting at the latest. As of September 30, 2026, Essity's holdings of own shares amounted to 7,458,875, corresponding to 1.1% of the total number of shares. Repurchased shares are expected to be canceled. The buybacks will be financed using cash flow from current operations after the ordinary dividend with the ambition to continue with share buybacks over time as a recurring part of Essity's capital allocation.

Net debt



ROCE excl. IAC and ROE excl. IAC



Financial position

	2609	2509	2512
Working capital, SEKm	15,304	12,816	12,237
Capital employed, SEKm	122,588	114,289	112,583
Net debt, SEKm	24,952	30,306	26,543
Debt/equity ratio	0.26	0.36	0.31
Debt payment capacity, %	74	60	74
Net debt/EBITDA	1.04	1.20	1.03
Net debt/EBITDA excl. IAC	0.98	1.18	1.03

Return

%	2026:3	2025:3	2609	2509
ROCE	11.9	17.9	14.7	16.8
ROCE excl. IAC	15.5	17.6	16.4	17.1
ROE	9.8	16.3	12.4	14.8
ROE excl. IAC	13.2	15.9	14.1	15.2

Change in net debt

SEKm	2609	2509	2512
Net debt at the beginning of the period	-26,543	-30,769	-30,769
Net cash flow	-2,309	-2,201	42
Remeasurements to equity	5,371	1,208	2,423
Investments in non-operating assets through leases	-202	-207	-331
Translation differences	-1,269	1,663	2,092
Net debt at the end of the period	-24,952	-30,306	-26,543

Health & Medical

- Higher prices and stable volumes
- High growth in North America
- Higher EBITA and margin, excl. IAC

Net sales

Net sales increased organically by 1.2%, driven by higher sales prices.

Growth was high in North America, while sales were stable in Europe and declined in Latin America.

In Incontinence Products, both higher volumes and sales prices supported organic growth.

Higher sales prices were the main driver for Medical Solutions, with good growth noted in wound care.

EBITA excl. IAC

EBITA and the EBITA margin excl. IAC were higher. Earnings were positively impacted by higher sales prices and lower sales and administration costs. Costs of goods sold were higher. Currency translation effects impacted earnings positively by SEK 22m.



With its five new models and standard sizes, JOBST® Elvarex® Soft now offers a comprehensive product range, making it easier for patients to find the right fit.

Change in net sales

%	2026:3 vs 2025:3
Total	2.7
Volume	-0.1
Price/Mix	1.3
Organic growth	1.2
Acquisitions	0.0
Divestments	0.0
Currency translation	1.5

Organic sales growth

%	2026:3 vs 2025:3	% of net sales
Incontinence Products Health Care	1.5	57
Medical Solutions	0.7	43


Financial overview

	2026:3	2025:3	%
Net sales, SEKm	7,066	6,883	3
Organic sales growth, %	1.2	1.7	
Gross profit margin excl. IAC, %	43.2	43.8	
EBITA excl. IAC, SEKm	1,302	1,260	3
EBITA margin excl. IAC, %	18.4	18.3	
ROCE excl. IAC, %	15.6	15.3	
Operating cash flow, SEKm	1,657	1,471	13


Net sales 2609 by region



Net sales



EBITA excl. IAC



Personal Care

- **Higher volumes and market shares**
- **High growth in North America and Latin America**
- **High growth in Incontinence Products and Feminine Care**

Net sales

Net sales increased organically by 3.2%, primarily driven by good volume growth. The product mix was also favorable, while sales prices were lower. Market shares increased for branded sales.

Growth was high in North America and Latin America, while sales were stable in Europe.

Incontinence Products and Feminine Care reported high organic growth, primarily due to strong volume growth, and strengthened their market shares during the quarter. In Baby Care, volumes were negatively impacted by a shrinking market, while the market positions of the leading brand, Libero, were further strengthened.

EBITA excl. IAC

EBITA excl. IAC increased, while the EBITA margin excl. IAC decreased. Earnings were positively impacted by higher volumes and negatively impacted by lower sales prices, higher costs of goods sold, sales and marketing as well as temporary integration costs related to the acquisition in Feminine Care in North America. Currency translation effects had a positive impact on earnings of SEK 88m.



The upgraded Saba Ultra Thin Night Pads combine our patented SmartProtect™ absorption technology with a wider absorbent core and an ultra-soft topsheet, providing superior protection, enhanced comfort, and peace of mind all night long.

Change in net sales

%	2026:3 vs 2025:3
Total	16.1
Volume	3.1
Price/Mix	0.1
Organic growth	3.2
Acquisitions	8.2
Divestments	0.0
Currency translation	4.7


Organic sales growth

%	2026:3 vs 2025:3	% of net sales
Incontinence Products Retail	5.1	34
Feminine Care	5.6	48
Baby Care	-3.9	18


Financial overview

	2026:3	2025:3	%
Net sales, SEKm	9,205	7,927	16
Organic sales growth, %	3.2	4.5	
Gross profit margin excl. IAC, %	39.6	40.9	
EBITA excl. IAC, SEKm	1,241	1,110	12
EBITA margin excl. IAC, %	13.5	14.0	
ROCE excl. IAC, %	21.5	24.0	
Operating cash flow, SEKm	1,610	1,133	42


Net sales 2609 by region



Net sales



EBITA excl. IAC



Consumer Tissue

- Lower volumes and sales prices
- Ongoing price increases, with sequentially higher prices

Net sales

Net sales decreased organically by 3.0% due to lower volumes, mainly driven by optimization of the production footprint in Latin America, as well as lower sales prices related to price adjustments in previous quarters. Sales prices were higher compared with the second quarter.

Sales declined in both Europe and Latin America.

EBITA excl. IAC

EBITA and the EBITA margin excl. IAC decreased, mainly due to higher costs of goods sold, but also lower sales prices and volumes had a negative impact. Sales and administration costs were lower. Currency translation effects had a positive impact on earnings of SEK 39m.



Regio Luxury Almond Touch has been upgraded with Ultimate Touch™, featuring superior softness, new embossing, clearer product benefits and an exclusive design, strengthening the brand's competitiveness in the premium segment.


Change in net sales

%	2026:3 vs 2025:3
Total	-1.1
Volume	-1.9
Price/Mix	-1.1
Organic growth	-3.0
Acquisitions	0.0
Divestments	0.0
Currency translation	1.9


Financial overview

	2026:3	2025:3	%
Net sales, SEKm	10,541	10,656	-1
Organic sales growth, %	-3.0	-1.9	
Gross profit margin excl. IAC, %	18.1	21.8	
EBITA excl. IAC, SEKm	908	1,252	-27
EBITA margin excl. IAC, %	8.6	11.7	
ROCE excl. IAC, %	9.9	14.1	
Operating cash flow, SEKm	502	947	-47


Net sales 2609 by region



Net sales



EBITA excl. IAC



Professional Hygiene

- Lower sales prices
- Lower volumes in the base assortment
- Growth in premium products

Net sales

Net sales decreased organically by 1.1%, due to lower volumes, mainly in the base assortment, and lower sales prices. The product mix remained favorable with an increased share of premium products.

Sales declined in North America and Europe, while remaining stable in Latin America.

EBITA excl. IAC

EBITA and the EBITA margin excl. IAC decreased, mainly due to lower prices and higher costs of goods sold. Sales and administration costs were lower. Currency translation effects had a positive impact on earnings of SEK 32m.



Tork Vision Cleaning enables data-driven cleaning through connected dispensers, people counting and real-time analytics, helping customers optimize cleaning resources, ensure product availability and enhance operational efficiency.


Change in net sales

%	2026:3 vs 2025:3
Total	0.8
Volume	-0.6
Price/Mix	-0.5
Organic growth	-1.1
Acquisitions	0.0
Divestments	0.0
Currency translation	1.9


Financial overview

	2026:3	2025:3	%
Net sales, SEKm	9,257	9,183	1
Organic sales growth, %	-1.1	0.7	
Gross profit margin excl. IAC, %	30.8	32.5	
EBITA excl. IAC, SEKm	1,575	1,676	-6
EBITA margin excl. IAC, %	17.0	18.3	
ROCE excl. IAC, %	23.2	26.2	
Operating cash flow, SEKm	2,160	1,880	15

Net sales 2609 by region



Net sales



EBITA excl. IAC, SEKm



First nine months 2026

Net sales

Net sales increased 0.5% compared with the corresponding period a year ago and amounted to SEK 104,298m (103,799). Excluding currency translation effects, net sales increased SEK 1,778m.

Sales increased organically by 0.1%. Higher volumes in Health & Medical, Personal Care and Professional Hygiene compensated for lower sales prices, mainly attributable to Consumer Tissue. The product mix was positive for the Group.

Operating profit

The gross profit margin amounted to 32.0% (33.2). The gross profit margin excl. IAC was 32.6% (33.2). Higher volumes and a positive product mix largely offset lower sales prices. Costs of goods sold were higher. Savings in costs of goods sold totaled approximately SEK 460m.

EBITA decreased 16% to SEK 12,189m (14,498), and EBITA excl. IAC decreased 3% to SEK 14,013m (14,455). Excluding currency translation effects, EBITA excl. IAC decreased 2%. The EBITA margin excl. IAC amounted to 13.4% (13.9). Sales and administration costs decreased and amounted to 19.1% (19.3), of which marketing costs accounted for 5.3% (5.2). Cost savings amounted to approximately SEK 280m. IAC totaled SEK -1,831m (62), of which approximately SEK 1,100m was attributable to the cost savings program and approximately SEK 500m to optimization of the production footprint in Consumer Tissue in Latin America.

Financial items

Financial items decreased to SEK -832m (-1,075), due to lower interest rates and lower average net debt.

Tax

The tax expense was SEK 2,673m (3,217), corresponding to a tax rate of 25.2% (25.3). The tax expense excl. IAC was SEK 3,151m (3,197), corresponding to a tax rate of 25.3% (25.3).

Profit for the period

Profit for the period was SEK 7,940m (9,494).

Group	2609	2509	%
Net sales, SEKm	104,298	103,799	0
Organic sales growth, %	0.1	1.7	
Gross profit margin excl. IAC, %	32.6	33.2	
EBITA excl. IAC, SEKm	14,013	14,455	-3
EBITA margin excl. IAC, %	13.4	13.9	
ROCE excl. IAC, %	16.4	17.1	
Operating cash flow, SEKm	12,927	10,629	22

Health & Medical	2609	2509	%
Net sales, SEKm	20,483	20,542	0
Organic sales growth, %	1.6	1.1	
Gross profit margin excl. IAC, %	44.3	44.0	
EBITA excl. IAC, SEKm	3,805	3,650	4
EBITA margin excl. IAC, %	18.6	17.8	
ROCE excl. IAC, %	15.6	15.1	
Operating cash flow, SEKm	3,609	3,101	16

Personal Care	2609	2509	%
Net sales, SEKm	26,200	23,674	11
Organic sales growth, %	3.7	3.7	
Gross profit margin excl. IAC, %	40.6	41.8	
EBITA excl. IAC, SEKm	3,634	3,428	6
EBITA margin excl. IAC, %	13.9	14.5	
ROCE excl. IAC, %	21.9	25.6	
Operating cash flow, SEKm	3,264	2,002	63

Consumer Tissue	2609	2509	%
Net sales, SEKm	31,099	32,628	-5
Organic sales growth, %	-3.9	1.2	
Gross profit margin excl. IAC, %	19.4	21.4	
EBITA excl. IAC, SEKm	3,008	3,745	-20
EBITA margin excl. IAC, %	9.7	11.5	
ROCE excl. IAC, %	12.5	13.5	
Operating cash flow, SEKm	2,375	2,895	-18

Professional Hygiene	2609	2509	%
Net sales, SEKm	26,523	26,943	-2
Organic sales growth, %	1.0	0.7	
Gross profit margin excl. IAC, %	31.1	31.8	
EBITA excl. IAC, SEKm	4,459	4,614	-3
EBITA margin excl. IAC, %	16.8	17.1	
ROCE excl. IAC, %	23.7	25.3	
Operating cash flow, SEKm	4,064	3,424	19

Other Group information

Sustainability

Sustainability is integrated into Essity's strategy and is a priority, with ambitious Group targets in several areas. The outcome for two of the targets is presented below. More information on these and other targets can be found in Essity's Annual Report.

Science-based emissions targets:

2030 Target: -35% vs 2016

Reduction in absolute greenhouse gas emissions, Scope 1 and 2

2022	2023	2024	2025	9M 2026*
-17%	-27%	-27%	-27%	-30%

*Outcome for the last 12 months

Sustainable innovations:

Target: >50% annually

Percentage leading to social and/or environmental improvements

2022	2023	2024	2025	9M 2026
68%	85%	87%	80%	76%

Events during the quarter

Essity appoints Andreas Mattsson as new Chief Legal Officer

On July 7, Essity announced that it had appointed Andreas Mattsson as the new Chief Legal Officer and member of the company's Executive Management Team. He succeeds Mikael Schmidt who has decided to retire as of December 31, 2026. Andreas Mattsson comes from the role of General Counsel at Billerud, and will take office on January 1, 2027. He will also be responsible for compliance and risk management at Essity.

Essity acquires feminine care business in Brazil

On August 19, Essity announced that it had entered into an agreement to acquire Kenvue's feminine care business in Brazil, including the market-leading brands Carefree, Sempre Livre and o.b. The acquisition strengthens Essity's position as a market leader in feminine care in Latin America. The transaction is expected to close during the second quarter of 2027.

Essity's CFO to retire during 2027

On September 21, Essity announced that Fredrik Rystedt, following more than nine years as CFO and Executive Vice President at the company, had informed the company of his wish to retire during 2027. The process of appointing a successor is ongoing and Fredrik Rystedt will remain in his current role until a successor has been appointed and an orderly handover has been completed.

Stockholm, October 22, 2026
Essity Aktiebolag (publ)

Ulrika Kolsrud
President and CEO

NB: This information is such that Essity Aktiebolag (publ) is obligated to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. This report has been prepared in both Swedish and English versions. In case of variations in the content between the two versions, the Swedish version shall govern. The information was submitted for publication, through the agency of Karl Stoltz, Public Relations Director, at 07:00 CET on October 22, 2026.

This report has not been reviewed by the company's auditors.

Financial statements

Condensed consolidated income statement

SEKm	2026:3	2025:3	%	2609	2509	%
Net sales	36,060	34,638	4	104,298	103,799	0
Cost of goods sold	-24,618	-23,065		-70,326	-69,351	
Items affecting comparability (IAC) - cost of goods sold	-608	25		-583	3	
Gross profit	10,834	11,598	-7	33,389	34,451	-3
Gross profit excl. IAC	11,442	11,573	-1	33,972	34,448	-1
Sales, general and administration	-6,717	-6,517		-19,959	-19,993	
Items affecting comparability (IAC) - sales, general and administration	-481	71		-1,241	40	
Operating profit before amortization of acquisition-related intangible assets (EBITA)	3,636	5,152	-29	12,189	14,498	-16
Operating profit before amortization of acquisition-related intangible assets (EBITA) excl. IAC	4,725	5,056	-7	14,013	14,455	-3
Amortization of acquisition-related intangible assets	-267	-243		-771	-740	
Items affecting comparability (IAC) - acquisition-related intangible assets	—	—		-7	19	
Operating profit	3,369	4,909	-31	11,411	13,777	-17
Operating profit excl. IAC	4,458	4,813	-7	13,242	13,715	-3
Share of results of associates and joint ventures	1	-4		34	9	
Financial items	-275	-369		-832	-1,075	
Profit before tax	3,095	4,536	-32	10,613	12,711	-17
Profit before tax excl. IAC	4,184	4,440	-6	12,444	12,649	-2
Income taxes	-749	-1,178		-2,673	-3,217	
Profit for the period	2,346	3,358	-30	7,940	9,494	-16
Profit for the period excl. IAC	3,140	3,289	-5	9,293	9,452	-2
Items affecting comparability (IAC) before tax	-1,089	96		-1,831	62	
Items affecting comparability (IAC) after tax	-794	69		-1,353	42	
Tax on amortization of acquisition-related intangible assets	77	72		223	218	

SEKm	2026:3	2025:3	2609	2509
Earnings attributable to:				
Owners of the Parent company	2,346	3,341	7,914	9,448
Non-controlling interests	0	17	26	46
Profit for the period	2,346	3,358	7,940	9,494
Earnings per share				
-Owners of the Parent company				
Earnings per share before and after dilution effects, SEK	3.47	4.86	11.65	13.68
Average numbers of shares before and after dilution effects, million	677	687	680	691

Consolidated statement of comprehensive income

SEKm	2026:3	2025:3	%	2609	2509	%
Profit for the period	2,346	3,358	-12	7,940	9,494	-9
Other comprehensive income for the period						
Items that will not be reclassified to the income statement						
Actuarial gains/losses on defined benefit pension plans	380	795		5,370	1,206	
Fair value through other comprehensive income	-2	2		1	2	
Income tax attributable to components in other comprehensive income	-89	-192		-1,233	-307	
Total	289	605		4,138	901	

SEKm	2026:3	2025:3	2609	2509
Items that have been or may be reclassified subsequently to the income statement				
Cash flow hedges:				
Result from remeasurement of derivatives recognized in equity	959	-72	1,586	-556
Transferred to profit or loss for the period	-129	35	-69	109
Translation differences in foreign operations	2,481	-710	6,981	-8,257
Gains/losses from hedges of net investments in foreign operations	-226	341	-374	1,722
Income tax attributable to components in other comprehensive income	-156	-58	-297	-258
Total	2,929	-464	7,827	-7,240
Other comprehensive income for the period, net of tax	3,218	141	11,965	-6,339
Total comprehensive income for the period	5,564	3,499	19,905	3,155
Total comprehensive income attributable to:				
Owners of the Parent company	5,547	3,484	19,829	3,154
Non-controlling interests	17	15	76	1

Consolidated balance sheet

SEKm	Sep 30, 2026	Sep 30, 2025	Dec 31, 2025	SEKm	Sep 30, 2026	Sep 30, 2025	Dec 31, 2025
ASSETS				EQUITY AND LIABILITIES			
Non-current assets				Equity			
Goodwill	40,342	37,614	36,861	Owners of the Parent company			
Intangible assets	19,185	18,818	18,273	Share capital	2,350	2,350	2,350
Property, plant and equipment	50,094	46,130	46,308	Reserves	12,050	6,035	4,257
Right-of-use assets	3,784	3,807	3,752	Retained earnings including profit/loss for the period	82,801	75,181	79,018
Investments in associates and joint ventures	341	311	307	Equity attributable to owner of the Parent company	97,201	83,566	85,625
Shares and participations	8	8	8	Non-controlling interests	435	417	415
Surplus in funded pension plans	9,726	3,489	4,340	Total equity	97,636	83,983	86,040
Non-current financial assets	129	124	142				
Deferred tax assets	2,163	2,279	2,122	Non-current liabilities			
Other non-current assets	1,077	747	725	Non-current financial liabilities	25,372	32,011	31,386
Total non-current assets	126,849	113,327	112,838	Provisions for pensions	2,129	2,438	2,146
				Deferred tax liabilities	7,832	6,588	6,272
Current Assets				Other non-current provisions	496	410	384
Inventories	20,642	19,193	18,153	Other non-current liabilities	20	101	92
Trade receivables	24,109	22,425	21,332	Total non-current liabilities	35,849	41,548	40,280
Current tax assets	1,805	1,373	1,626				
Other current receivables	5,014	3,569	3,414	Current liabilities			
Current financial assets	1,021	1,491	1,266	Current financial liabilities	13,864	7,190	7,246
Non-current assets held for sale	24	13	—	Trade payables	16,304	14,672	14,437
Cash and cash equivalents	5,537	6,229	8,487	Current tax liabilities	1,794	1,501	1,847
Total current assets	58,152	54,293	54,278	Current provisions	1,465	982	1,200
Total assets	185,001	167,620	167,116	Other current liabilities	18,089	17,744	16,066
				Total current liabilities	51,516	42,089	40,796
				Total equity and liabilities	185,001	167,620	167,116

Consolidated statement of change in equity

SEKm	Sep 30, 2026	Sep 30, 2025	Dec 31, 2025
Equity attributable to owners of the Parent company			
Value, beginning of the period	85,625	88,314	88,314
Total comprehensive income for the period	19,829	3,154	5,734
Dividend	-5,956	-5,711	-5,711
Buyback of own shares	-2,283	-2,605	-3,160
Transferred to cost of hedged investments	14	5	6
Acquisition of non-controlling interest	-28	—	—
Revaluation effect upon acquisition of non-controlling interests	—	409	442
Value, end of period	97,201	83,566	85,625
Non-controlling interests			
Value, beginning of period	415	427	427
Total comprehensive income for the period	76	1	8
Dividend	—	-11	-20
Acquisition of non-controlling interests	-56	—	—
Value, end of period	435	417	415
Total equity, value end of period	97,636	83,983	86,040

Consolidated cash flow statement

SEKm	2609	2509	SEKm	2609	2509
Operating activities			Financing activities		
Operating profit	11,411	13,777	Acquisition of non-controlling interests	-83	—
Adjustments for non-cash items ¹⁾	7,365	5,770	Proceeds from borrowings	6,409	886
Capitalized expenditures to fulfill contracts with customers	-450	-362	Repayment of borrowings	-9,028	-5,056
Change in provisions relating to restructuring programs, etc.	-315	-249	Payment of lease liabilities	-820	-816
Cash flow from changes in working capital			Change in borrowings with short maturities, etc.	1,733	-464
Change in inventories	-673	-1,622	Dividend	-5,956	-5,711
Change in operating receivables	-1,529	79	Dividend to non-controlling interests	—	-11
Change in operating liabilities	1,813	-1,726	Repurchase of own shares	-2,283	-2,605
Cash flow from operations	17,622	15,667	Cash flow from financing activities	-10,028	-13,777
Interest paid	-1,431	-2,450	Cash flow for the period	-3,198	-4,478
Interest received	164	217	Cash and cash equivalents at the beginning of the period	8,487	10,962
Other financial items	-94	-57	Translation differences in cash and cash equivalents	248	-255
Income taxes paid	-3,094	-3,460	Cash and cash equivalents at the end of the period	5,537	6,229
Cash flow from operating activities	13,167	9,917			
Investing activities			¹⁾Adjustments for non-cash items		
Acquisitions of Group companies and other operations	-2,994	—	SEKm	2609	2509
Divestments of Group companies and other operations	—	5	Depreciation/amortization and impairment of non-current assets	5,924	5,296
Investments in intangible assets and property, plant and equipment	-4,313	-4,630	Depreciation of capitalized selling expenses	350	341
Paid interest capitalized in intangible assets and property, plant and equipment	-13	-9	Gain/loss on sale of assets	14	-67
Sale of property, plant and equipment	81	202	Gain/loss on divestment and liquidation	—	2
Purchase and sale of financial assets with short maturities	902	3,814	Non-cash items relating to restructuring program	662	79
Cash flow from investing activities	-6,337	-618	Other	415	119
			Total	7,365	5,770

Consolidated cash flow statement, cont.

Reconciliation with consolidated operating cash flow statement

SEKm	2609	2509
Cash flow for the period	-3,198	-4,478
Proceeds from borrowings	-6,409	-886
Repayment of borrowings	9,028	5,056
Payment of lease liabilities	820	816
Change in borrowings with short maturities, etc.	-1,733	464
Purchase and sale of financial assets with short maturities	-902	-3,814
Net debt in acquired and divested operations	-10	—
Investments in operating assets through leases	-434	-573
Accrued interest, etc.	529	1,214
Net cash flow according to consolidated operating cash flow statement	-2,309	-2,201

Condensed financial statements, Parent company

Condensed Parent company income statement

SEKm	2609	2509
Administrative expenses	-735	-688
Other operating income	278	183
Operating loss	-457	-505
Financial items	-568	12,185
Profit/loss before tax	-1,025	11,680
Income taxes	65	90
Profit/loss for the period	-960	11,770

Parent company statement of comprehensive income

SEKm	2609	2509
Profit/loss for the period	-960	11,770
Other comprehensive income for the period	—	—
Total comprehensive income for the period	-960	11,770

Condensed Parent company balance sheet

SEKm	Sep 30, 2026	Dec 31, 2025
Assets		
Intangible assets	0	0
Property, plant and equipment	9	11
Financial non-current assets	178,390	176,680
Total non-current assets	178,399	176,691
Total current assets	1,474	2,560
Total assets	179,873	179,251
Equity, provisions and liabilities		
Equity		
Restricted equity	2,350	2,350
Non-restricted equity	76,176	85,376
Total equity	78,526	87,726
Untaxed reserves	1,477	1,477
Provisions	812	830
Non-current liabilities	23,837	30,028
Current liabilities	75,221	59,190
Total equity, provisions and liabilities	179,873	179,251

Notes

Note 1 Accounting principles

This interim report has been prepared in accordance with IAS 34 and recommendation RFR 1 of the Swedish Corporate Reporting Board and RFR 2 for the Parent company. The following amendments to IFRS® Accounting Standards have gained legal force from January 1, 2026. Essity Aktiebolag (publ) applies these amendments, which have not had any material impact on the Group's or the Parent company's financial statements.

- IFRS 9 Financial Instruments and IFRS 7 Financial Instruments: Disclosures have been amended with regard to classification and measurement of some specific financial instruments and disclosures.
- A number of other standards have been amended as part of the IASB's annual improvement process and include clarifications, simplifications, corrections and consistency improvements.

A new standard, IFRS 18 Presentation and Disclosures in Financial Statements was published on April 9, 2024, and is to be applied as of January 1, 2027. The standard includes new requirements regarding the presentation and disclosure of information in financial statements and, among other changes, introduces a new structure for the income statement with categories for operating, investing and financing activities, as well as new mandatory subtotals. The principles for aggregation and disaggregation have been clarified, and specific disclosure requirements have been introduced for management-defined performance measures (MPMs). Essity's implementation process is ongoing and includes the structure of the future income statement, performance measures, and the required adjustments to reporting, systems and processes, as well as the preparation of comparative information.

In other respects, the accounting principles and calculation methods applied correspond to those described in Essity's 2025 Annual Report.

Note 2 Risks and uncertainties

Processes for risk management

Essity's Board determines the Group's strategic direction based on recommendations from the Executive Management Team. Responsibility for the long-term, overall management of strategic risks corresponds to the company's delegation structure, from the Board of Directors to the CEO and from the CEO to the Business Area Presidents. This means that most operational risks are managed by Essity's business

areas at the local level, but they are centrally coordinated when considered necessary. The tools used for coordination consist primarily of the business areas regular reporting and the annual strategy process, which includes risks and risk management.

Essity's financial risk management is centralized, as is its internal bank for financial transactions conducted by Group companies and the management of the Group's energy risks. Financial risks are managed in accordance with the Group's Finance Policy, which is adopted by Essity's Board and, together with Essity's Energy Risk Policy, provides a management framework. Risks are continuously compiled and monitored to ensure compliance with these guidelines. Essity has also centralized other risk management.

Essity has a staff function for internal audit, which monitors compliance with the Group's policies.

Essity's risk exposure and risk management are described on pages 41–46 in the 2025 Annual Report and in the sections under environmental information and social information on pages 58–60. No significant changes have taken place that have affected the reported risks.

Risks in conjunction with company acquisitions are analyzed in the due diligence processes that Essity carries out prior to all acquisitions. In cases where acquisitions have been carried out that may affect the assessment of Essity's risk exposure, these are described under the heading "Events during the quarter" in the interim or year-end reports.

Ongoing geopolitical tensions, such as the war in Iran and the conflicts in and around the Persian Gulf, contribute to increased economic uncertainty and rising commodity prices. The prices of oil and gas have increased significantly following the outbreak of the war. Changes in prices of commodities such as oil and gas may directly or indirectly affect the Group's financial position and operating profit as a result of higher costs, price increases and reduced purchasing power among customers and consumers.

Note 3 Financial assets and liabilities

Measurement principles and classifications of financial instruments, as described in Essity's 2025 Annual Report, Note E1, were applied consistently throughout the reporting period. Financial liabilities are measured at amortized cost provided they are not part of a fair value hedge when they are recognized at fair value through profit or loss. The fair value of trade receivables, other current and non-current receivables, cash and cash equivalents, trade payables and other current and non-current liabilities is estimated to be equal to their carrying amount.

SEKm	Carrying amount	Fair value	Carrying amount	Fair value	Measurement level ¹⁾
	Sep 30, 2026	Sep 30, 2026	Dec 31, 2025	Dec 31, 2025	
Assets					
Derivatives	2,598	2,598	506	506	2
Non-current financial assets	112	112	106	106	1
Total assets	2,710	2,710	612	612	
Liabilities					
Derivatives	1,206	1,206	1,607	1,607	2
Current financial liabilities ²⁾	11,881	11,881	5,707	5,707	2
Non-current financial liabilities ²⁾	22,247	21,864	27,692	27,192	2
Total liabilities	35,334	34,951	35,006	34,506	

¹⁾ No financial instruments have been classified to level 3.

²⁾ The measurement level refers to liabilities measured at fair value in a hedging relationship.

Note 4 The share

Number of shares

	2026:3	2025:3	2609	2509
Number of shares, end of period	681,945,171	693,054,489	681,945,171	693,054,489
Of which Class A shares	53,963,041	58,473,654	53,963,041	58,473,654
Of which Class B shares	627,982,130	634,580,835	627,982,130	634,580,835
Number of shares held by Essity, end of period	7,458,875	7,855,598	7,458,875	7,855,598
Number of outstanding shares before and after dilution, end of period	674,486,296	685,198,891	674,486,296	685,198,891
Average number of Class B shares held by Essity	5,283,642	5,694,757	6,085,999	5,509,224
Average number of shares before and after dilution	676,661,529	687,359,732	679,521,584	690,675,287

Note 5 Acquisitions and divestments

On November 12, 2025, Essity announced that it had acquired Edgewell Personal Care's feminine care business, including the brands Carefree, Stayfree and o.b. in North America and Playtex globally. The preliminary purchase price allocation presented in Essity's 2025 Annual Report has subsequently been adjusted based on additional information on the opening balance of the business obtained after completion of the acquisition.

The acquisition strengthens Essity's presence in feminine care in North America and enables expected synergies, and goodwill has thus been recognized. The business has about 500 employees and reported net sales of USD 264m (SEK 2,583m) in 2025.

The purchase price for the assets amounted to USD 339m (SEK 2,994m) as well as the take-over of net debt of SEK 10m. The acquisition supports Essity's strategy to focus on categories that yield a high return and to strengthen the company's market position in the USA, the world's largest hygiene market.

The acquisition was consolidated into Essity's consolidated financial statements from February 2, 2026. From the date of consolidation, reported net sales amounted to SEK 1,604m, EBITDA to SEK 36m and EBITA to SEK -27m. If the acquisition had been consolidated as of January 1, 2026, net sales would have amounted to SEK 1,820m, EBITDA to SEK 49m and EBITA to SEK -23m. Acquisition costs amounted to SEK 118m and were recognized as IAC.

Purchase price allocation	SEKm
Intangible assets	1,099
Property, plant and equipment	603
Operating assets	524
Net debt excluding cash and cash equivalents	-10
Operating liabilities	-85
Fair value of net assets	2,131
Goodwill	863
Consideration transferred	2,994
Consideration transferred	-2,994
Acquired net debt excluding cash and cash equivalents	-10
Acquisitions of Group companies and other operations during the period, including net debt assumed	-3,004

Note 5 cont.

On August 19, 2026, Essity announced that it had entered into an agreement to acquire Kenvue's feminine care business in Brazil, including the market-leading brands Carefree, Sempre Livre and o.b. The purchase price amounts to USD 284m (approximately SEK 2.7bn) on a cash and debt-free basis. The acquisition strengthens Essity's position as a market leader in feminine care in Latin America. The transaction is still subject to regulatory approval in Brazil and other customary closing conditions as well as the completion of the Kimberly-Clark and Kenvue transaction and is expected to close during the second quarter of 2027.

Note 6 Use of non-International Financial Reporting Standards (IFRS®) performance measures

Guidelines for Alternative Performance Measures (APMs) for companies with securities listed on a regulated market in the EU have been issued by ESMA (European Securities and Markets Authority). These guidelines are to be applied for APMs not supported under IFRS.

This interim report refers to a number of performance measures not defined in IFRS. These performance measures are used to help investors, management and other stakeholders to analyze the company's operations. These non-IFRS performance measures may differ from similarly titled measures among other companies. Essity's 2025 Annual Report, pages 120–124, describes the various non-IFRS performance measures that are used as a complement to the financial information presented in accordance with IFRS. Abbreviations are used in the report for the performance and return measures below.

Abbreviation	Complete expression
EBITA	Operating profit before amortization of acquisition-related intangible assets
EBITDA	Operating profit before depreciation and amortization of property, plant and equipment and intangible assets
IAC	Items affecting comparability
ROCE	Return on capital employed
ROE	Return on equity

Capital employed

SEKm	2609	2509	2512
Total assets	185,001	167,620	167,116
-Financial assets	-16,413	-11,333	-14,235
-Non-current non-interest bearing liabilities	-8,348	-7,099	-6,748
-Current non-interest bearing liabilities	-37,652	-34,899	-33,550
Capital employed	122,588	114,289	112,583

Working capital

SEKm	2609	2509	2512
Inventories	20,642	19,193	18,153
Trade receivables	24,109	22,425	21,332
Other current receivables	5,014	3,569	3,414
Trade payables	-16,304	-14,672	-14,437
Other current liabilities	-18,089	-17,744	-16,066
Other	-68	45	-159
Working capital	15,304	12,816	12,237

Note 6 cont.

Net debt

SEKm	2609	2509	2512
Surplus in funded pension plans	9,726	3,489	4,340
Non-current financial assets	129	124	142
Current financial assets	1,021	1,491	1,266
Cash and cash equivalents	5,537	6,229	8,487
Financial assets	16,413	11,333	14,235
Non-current financial liabilities	25,372	32,011	31,386
Provisions for pensions	2,129	2,438	2,146
Current financial liabilities	13,864	7,190	7,246
Financial liabilities	41,365	41,639	40,778
Net debt	24,952	30,306	26,543

EBITA

SEKm	2026:3	2025:3	2609	2509
Operating profit	3,369	4,909	11,411	13,777
-Amortization of acquisition-related intangible assets	267	243	771	740
-Items affecting comparability (IAC) - impairment of acquisition-related intangible assets	0	0	7	-19
Operating profit before amortization and impairment of acquisition-related intangible assets (EBITA)	3,636	5,152	12,189	14,498
EBITA margin (%)	10.1	14.9	11.7	14.0
-Items affecting comparability (IAC) - cost of goods sold	608	-25	583	-3
-Items affecting comparability (IAC) - sales, general and administration	481	-71	1,241	-40
EBITA excl. IAC	4,725	5,056	14,013	14,455
EBITA margin excl. IAC (%)	13.1	14.6	13.4	13.9

EBITDA

SEKm	2026:3	2025:3	2609	2509
Operating profit	3,369	4,909	11,411	13,777
-Amortization of acquisition-related intangible assets	267	243	771	740
-Depreciation/amortization	1,405	1,245	3,924	3,694
-Depreciation right-of-use asset	293	277	839	834
-Impairment	0	23	19	33
-Items affecting comparability (IAC) - impairment net	362	10	364	14
-Items affecting comparability (IAC) - impairment of acquisition-related intangible assets	—	—	7	-19
EBITDA	5,696	6,707	17,335	19,073
-Items affecting comparability (IAC) excluding depreciation/amortization and impairment	727	-106	1,460	-57
EBITDA excl. IAC	6,423	6,601	18,795	19,016

Sales growth

SEKm	2026:3	2025:3	2609	2509
Organic sales growth	-98	329	144	1,782
Acquisitions	649	—	1,634	—
Divestments	—	-7	—	-28
Exchange rate effect ¹⁾	870	-1,958	-1,279	-5,696
Recognized change	1,421	-1,636	499	-3,942

¹⁾ Consists solely of currency translation effects

Note 7 Segment reporting

Effective January 1, 2026, Essity has implemented an organizational change, simplifying its structure and creating end-to-end accountability. This aims to further enhance customer and consumer focus, while increasing speed, agility and operational efficiency throughout the Group. The change facilitates increased strategic focus on the product categories and segments with the greatest potential for profitable growth. The new organization consists of the business areas Health & Medical, Personal Care, Consumer Tissue and Professional Hygiene, with clear overall responsibility in each business area for innovation, production, marketing and sales. The former Consumer Goods business area has been split into Personal Care and Consumer Tissue. Essity's former global units Global Marketing & Innovation and Global Supply Chain have been integrated into the four business areas. The tables below show parts of the income statement broken down by operating segment: Health & Medical, Personal Care, Consumer Tissue and Professional Hygiene. For additional information, refer to page 26.

SEKm						2026:3
	Health & Medical	Personal Care	Consumer Tissue	Professional Hygiene	Other operations	Total Group
Net sales	7,066	9,205	10,541	9,257	-9	36,060
Cost of goods sold	-4,011	-5,561	-8,634	-6,407	-5	-24,618
Sales, general and administration	-1,753	-2,403	-999	-1,275	-287	-6,717
Operating profit/loss before amortization of acquisition-related intangible assets (EBITA) excl. IAC	1,302	1,241	908	1,575	-301	4,725
Amortization of acquisition-related intangible assets	-185	-77	-2	-5	2	-267
Operating profit excl. IAC	1,117	1,164	906	1,570	-299	4,458
Items affecting comparability (IAC)	-93	-76	-702	-97	-121	-1,089
Operating profit/loss	1,024	1,088	204	1,473	-420	3,369
Share of results of associates and joint ventures						1
Financial items						-275
Tax expense for the period						-749
Profit for the period						2,346

SEKm						2025:3
	Health & Medical	Personal Care	Consumer Tissue	Professional Hygiene	Other operations	Total Group
Net sales	6,883	7,927	10,656	9,183	-11	34,638
Cost of goods sold	-3,866	-4,686	-8,332	-6,197	16	-23,065
Sales, general and administration	-1,757	-2,131	-1,072	-1,310	-247	-6,517
Operating profit/loss before amortization of acquisition-related intangible assets (EBITA) excl. IAC	1,260	1,110	1,252	1,676	-242	5,056
Amortization of acquisition-related intangible assets	-184	-54	-1	-5	1	-243
Operating profit excl. IAC	1,076	1,056	1,251	1,671	-241	4,813
Items affecting comparability (IAC)	-14	-1	93	20	-2	96
Operating profit/loss	1,062	1,055	1,344	1,691	-243	4,909
Share of results of associates and joint ventures						-4
Financial items						-369
Tax expense for the period						-1,178
Profit for the period						3,358

SEKm						2609
	Health & Medical	Personal Care	Consumer Tissue	Professional Hygiene	Other operations	Total Group
Net sales	20,483	26,200	31,099	26,523	-7	104,298
Cost of goods sold	-11,412	-15,570	-25,070	-18,278	4	-70,326
Sales, general and administration	-5,266	-6,996	-3,021	-3,786	-890	-19,959
Operating profit/loss before amortization of acquisition-related intangible assets (EBITA) excl. IAC	3,805	3,634	3,008	4,459	-893	14,013
Amortization of acquisition-related intangible assets	-537	-217	-3	-15	1	-771
Operating profit excl. IAC	3,268	3,417	3,005	4,444	-892	13,242
Items affecting comparability (IAC)	-246	-288	-764	-278	-255	-1,831
Operating profit/loss	3,022	3,129	2,241	4,166	-1,147	11,411
Share of results of associates and joint ventures						34
Financial items						-832
Tax expense for the period						-2,673
Profit for the period						7,940

SEKm						2509
	Health & Medical	Personal Care	Consumer Tissue	Professional Hygiene	Other operations	Total Group
Net sales	20,542	23,674	32,628	26,943	12	103,799
Cost of goods sold	-11,506	-13,779	-25,648	-18,383	-35	-69,351
Sales, general and administration	-5,386	-6,467	-3,235	-3,946	-959	-19,993
Operating profit/loss before amortization of acquisition-related intangible assets (EBITA) excl. IAC	3,650	3,428	3,745	4,614	-982	14,455
Amortization of acquisition-related intangible assets	-558	-164	-3	-16	1	-740
Operating profit excl. IAC	3,092	3,264	3,742	4,598	-981	13,715
Items affecting comparability (IAC)	-1	-2	100	-1	-34	62
Operating profit/loss	3,091	3,262	3,842	4,597	-1,015	13,777
Share of results of associates and joint ventures						9
Financial items						-1,075
Tax expense for the period						-3,217
Profit for the period						9,494

Other financial information

Group information by quarter

	2026:3	2026:2	2026:1	2025:4	2025:3	2025:2	2025:1	2024:4	2024:3
Net sales, SEKm	36,060	35,061	33,177	34,695	34,638	34,185	34,976	37,805	36,274
Organic sales growth, %	-0.3	0.3	0.4	-1.1	0.9	1.9	2.1	3.9	1.9
Gross profit, SEKm	10,834	11,446	11,109	11,671	11,598	11,389	11,464	11,968	11,962
Gross profit excl. IAC, SEKm	11,442	11,445	11,085	11,695	11,573	11,401	11,474	12,074	11,826
EBITA, SEKm	3,636	4,105	4,448	5,005	5,152	4,628	4,718	4,585	5,130
EBITA excl. IAC, SEKm	4,725	4,685	4,603	5,117	5,056	4,693	4,706	4,969	5,097
Operating profit, SEKm	3,369	3,846	4,196	4,754	4,909	4,386	4,482	4,315	4,868
Profit for the period, SEKm	2,346	2,693	2,901	3,224	3,358	3,053	3,083	2,893	3,329
Operating cash flow, SEKm	5,783	2,790	4,354	4,369	5,324	1,540	3,765	3,297	6,453
ROCE, %	11.9	14.0	15.8	17.6	17.9	16.7	16.7	15.8	17.8
ROCE excl. IAC, %	15.5	16.0	16.3	18.0	17.6	16.9	16.7	17.1	17.7
Capital employed, SEKm	122,588	121,642	112,699	112,583	114,289	115,384	106,478	119,510	112,957
ROE, %	9.8	11.9	13.3	15.2	16.3	15.2	14.6	13.4	15.9
ROE excl. IAC, %	13.2	13.7	14.0	15.6	15.9	15.4	14.5	14.9	15.8
Debt/equity ratio	0.26	0.31	0.28	0.31	0.36	0.42	0.34	0.35	0.35
Equity/assets ratio, %	52.5	51.1	48.5	51.2	49.9	48.3	46.3	47.7	46.2
Net debt, SEKm	24,952	28,462	24,538	26,543	30,306	34,177	26,774	30,769	29,122
Earnings per share, SEK	3.47	3.94	4.23	4.69	4.86	4.39	4.43	4.13	4.73
Earnings per share excl. IAC, SEK	4.92	4.83	4.70	5.07	5.01	4.71	4.65	4.85	4.97
Equity per share, SEK	144	137	129	125	122	117	115	127	119

Margins (%)	2026:3	2026:2	2026:1	2025:4	2025:3	2025:2	2025:1	2024:4	2024:3
Gross profit margin	30.0	32.6	33.5	33.6	33.5	33.3	32.8	31.7	33.0
Gross profit margin excl. IAC	31.7	32.6	33.4	33.7	33.4	33.4	32.8	31.9	32.6
EBITA margin	10.1	11.7	13.4	14.4	14.9	13.5	13.5	12.1	14.1
EBITA margin excl. IAC	13.1	13.4	13.9	14.7	14.6	13.7	13.5	13.1	14.1
Operating margin	9.3	11.0	12.6	13.7	14.2	12.8	12.8	11.4	13.4
Operating margin excl. IAC	12.4	12.6	13.1	14.1	13.9	13.0	12.7	12.4	13.3
Sh of results of assoc. and JV	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Financial net margin	-0.8	-0.9	-0.8	-0.9	-1.1	-1.0	-1.1	-1.1	-1.2
Profit margin	8.5	10.2	11.8	12.8	13.1	11.8	11.7	10.3	12.2
Profit margin excl. IAC	11.6	11.8	12.3	13.2	12.8	12.0	11.6	11.3	12.1
Income taxes	-2.1	-2.5	-3.1	-3.5	-3.4	-3.0	-2.9	-2.7	-3.1
Income taxes excl. IAC	-2.9	-3.0	-3.2	-3.6	-3.3	-3.0	-2.9	-2.8	-3.0
Net margin	6.4	7.7	8.7	9.3	9.7	8.8	8.8	7.6	9.1
Net margin excl. IAC	8.7	8.8	9.1	9.6	9.5	9.0	8.7	8.5	9.1

Information by business area

Net sales

SEKm	2026:3	2026:2	2026:1	2025:4	2025:3	2025:2	2025:1	2024:4	2024:3
Health & Medical	7,066	6,918	6,499	6,926	6,883	6,723	6,936	7,417	7,127
Personal Care	9,205	8,815	8,180	7,884	7,927	7,763	7,984	8,411	8,083
Consumer Tissue	10,541	10,202	10,356	10,909	10,656	10,671	11,301	12,061	11,327
Professional Hygiene	9,257	9,127	8,139	8,961	9,183	9,003	8,757	9,923	9,729
Other	-9	-1	3	15	-11	25	-2	-7	8
Group	36,060	35,061	33,177	34,695	34,638	34,185	34,976	37,805	36,274

Organic sales growth

%	2026:3	2026:2	2026:1	2025:4	2025:3	2025:2	2025:1	2024:4	2024:3
Health & Medical	1.2	3.1	0.5	0.7	1.7	0.1	1.7	5.6	2.8
Personal Care	3.2	3.8	4.1	1.5	4.5	3.6	3.0	4.8	4.4
Consumer Tissue	-3.0	-5.3	-3.5	-4.4	-1.9	2.9	2.7	4.3	2.0
Professional Hygiene	-1.1	2.1	1.9	-0.8	0.7	0.6	0.7	1.4	-0.8
Group	-0.3	0.3	0.4	-1.1	0.9	1.9	2.1	3.9	1.9

EBITA excl. IAC

SEKm	2026:3	2026:2	2026:1	2025:4	2025:3	2025:2	2025:1	2024:4	2024:3
Health & Medical	1,302	1,310	1,193	1,296	1,260	1,159	1,231	1,361	1,386
Personal Care	1,241	1,131	1,262	990	1,110	1,120	1,198	1,221	1,261
Consumer Tissue	908	988	1,112	1,442	1,252	1,248	1,245	1,024	1,024
Professional Hygiene	1,575	1,573	1,311	1,750	1,676	1,525	1,413	1,817	1,812
Other	-301	-317	-275	-361	-242	-359	-381	-454	-386
Group	4,725	4,685	4,603	5,117	5,056	4,693	4,706	4,969	5,097

EBITA margin excl. IAC

%	2026:3	2026:2	2026:1	2025:4	2025:3	2025:2	2025:1	2024:4	2024:3
Health & Medical	18.4	18.9	18.4	18.7	18.3	17.2	17.7	18.3	19.4
Personal Care	13.5	12.8	15.4	12.6	14.0	14.4	15.0	14.5	15.6
Consumer Tissue	8.6	9.7	10.7	13.2	11.7	11.7	11.0	8.5	9.0
Professional Hygiene	17.0	17.2	16.1	19.5	18.3	16.9	16.1	18.3	18.6
Group	13.1	13.4	13.9	14.7	14.6	13.7	13.5	13.1	14.1

Capital employed

SEKm	2026:3	2026:2	2026:1	2025:4	2025:3	2025:2	2025:1	2024:4	2024:3
Health & Medical	33,537	33,193	32,430	31,577	32,673	33,352	32,366	34,566	33,112
Personal Care	23,268	23,030	22,593	18,299	18,621	18,405	17,913	18,593	17,238
Consumer Tissue	37,000	36,104	35,059	34,744	35,512	35,442	34,180	36,700	35,322
Professional Hygiene	27,290	27,132	26,347	25,176	25,311	25,850	25,494	25,998	24,501
Other	1,493	2,183	-3,730 ¹⁾	2,787	2,172	2,335	-3,475 ²⁾	3,653	2,784
Group	122,588	121,642	112,699	112,583	114,289	115,384	106,478	119,510	112,957

¹⁾ 2026:1: Of this amount, SEK 5,956m represents a liability relating to the dividend for Essity's shareholders paid on April 2, 2026, as decided at the Annual General Meeting on March 26, 2026.

²⁾ Of this amount, SEK 5,711m represents a liability relating to the dividend for Essity's shareholders paid on April 3, 2025, as decided at the Annual General Meeting on March 27, 2025.

ROCE excl. IAC

%	2026:3	2026:2	2026:1	2025:4	2025:3	2025:2	2025:1	2024:4	2024:3
Health & Medical	15.6	16.0	14.9	16.1	15.3	14.1	14.7	16.1	16.5
Personal Care	21.5	19.8	24.7	21.5	24.0	24.7	26.2	27.3	28.4
Consumer Tissue	9.9	11.1	12.8	16.4	14.1	14.3	14.1	11.4	11.5
Professional Hygiene	23.2	23.5	20.4	27.7	26.2	23.8	22.0	28.8	28.7
Group	15.5	16.0	16.3	18.0	17.6	16.9	16.7	17.1	17.7

Operating cash flow

SEKm	2026:3	2026:2	2026:1	2025:4	2025:3	2025:2	2025:1	2024:4	2024:3
Health & Medical	1,657	872	1,080	1,538	1,471	398	1,232	976	1,674
Personal Care	1,610	868	786	541	1,133	654	215	400	1,822
Consumer Tissue	502	413	1,460	1,297	947	506	1,442	714	971
Professional Hygiene	2,160	1,100	804	1,922	1,880	490	1,054	1,678	2,153
Other	-146	-463	224	-929	-107	-508	-178	-471	-167
Group	5,783	2,790	4,354	4,369	5,324	1,540	3,765	3,297	6,453

Invitation to presentation

President and CEO Ulrika Kolsrud and Executive Vice President and CFO Fredrik Rystedt will present the report at a live webcast and teleconference at 09:00 a.m. CEST on October 22, 2026.

Link to the live presentation, which can also be viewed afterwards:
<https://essity.videosync.fi/2026-10-22>

Contact information for conference call with the possibility to ask questions:

UK: +44 (0) 33 0551 02 00

USA: +1 786 697 35 01

SWE: +46 (0) 8 505 204 24

Please call in well in advance of the start of the presentation. Indicate: "Essity".

Financial calendar 2027

Report for quarter 4 and full-year 2026	January 21, 2027
Annual Report 2026	February/March, 2027
Annual General Meeting	April 7, 2027
Interim report, Quarter 1, 2027	April 22, 2027
Interim report, Quarter 2, 2027	July 15, 2027
Interim report, Quarter 3, 2027	October 21, 2027

For additional information

Fredrik Rystedt, Executive Vice President and CFO, tel: +46 (0) 8 788 51 31
Sandra Åberg, Vice President Investor Relations, tel: +46 (0) 70 564 96 89
Per Lorentz, Vice President Corporate Affairs, tel: +46 (0) 73 313 30 55

Essity is a global, leading hygiene and health company. Every day, our products, solutions and services are used by a billion people around the world. Our purpose is to break barriers to well-being for the benefit of consumers, patients, caregivers, customers and society. Sales are conducted in approximately 150 countries under the leading global brands TENA and Tork, and other strong brands such as Actimove, Cutimed, JOBST, Knix, Leukoplast, Libero, Libresse, Lotus, Modibodi, Nosotras, Saba, Tempo, TOM Organic and Zewa. In 2025, Essity had net sales of approximately SEK 138bn (EUR 13bn) and employed 36,000 people. The company's headquarter is in Stockholm, Sweden and Essity is listed on Nasdaq Stockholm.

More information at essity.com and follow Essity on social media.

